Related Experiment Video
Updated: Jul 18, 2025
06:56
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
411
MAPK13 stabilization via m6A mRNA modification limits anticancer efficacy of rapamycin
Joohwan Kim1, Yujin Chun1, Cuauhtemoc B Ramirez2
1Department of Microbiology and Molecular Genetics, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, California, USA.
The Journal of Biological Chemistry
|August 20, 2023
Summary
Rapamycin resistance in cancer is linked to m6A modification of MAPK13 mRNA. Inhibiting MAPK13 may improve rapamycin
Area of Science:
- Epigenetics and RNA modifications
- Cancer biology and drug resistance
- Molecular mechanisms of gene regulation
Background:
- N6-adenosine methylation (m6A) is a key mRNA modification influencing gene expression and cancer development.
- The role of m6A in cancer drug response and resistance remains largely unexplored.
- Understanding m6A's role in drug resistance is crucial for developing effective cancer therapies.
Purpose of the Study:
- To investigate the role of m6A modification in cancer cell sensitivity to rapamycin, an mTORC1 inhibitor.
- To elucidate the molecular mechanisms by which m6A affects MAPK13 mRNA stability and rapamycin response.
- To identify potential therapeutic targets for overcoming rapamycin resistance.
Main Methods:
- Analysis of m6A modification on mitogen-activated protein kinase 13 (MAPK13) mRNA.
- Investigating the involvement of the METTL3-METTL14-WTAP complex and YTHDF2 in MAPK13 mRNA regulation.
- Assessing the impact of rapamycin treatment on MAPK13 mRNA stability and cancer cell sensitivity.
- Evaluating the effects of genetic or pharmacological inhibition of MAPK13 on rapamycin efficacy.
Main Results:
- mTORC1 signaling induces m6A modification of MAPK13 mRNA, leading to its degradation.
- Rapamycin treatment inhibits this m6A-mediated degradation, stabilizing MAPK13 mRNA.
- Stabilized MAPK13 confers a pro-growth signal, contributing to rapamycin resistance in cancer cells.
- Inhibition of MAPK13 enhances the anticancer effects of rapamycin.
Conclusions:
- Rapamycin-induced stabilization of MAPK13 mRNA via m6A modification is a mechanism of drug resistance.
- MAPK13 represents a potential therapeutic target to sensitize cancer cells to rapamycin.
- Targeting MAPK13 could offer a novel strategy to improve the efficacy of mTORC1-targeting agents in cancer treatment.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
02:51mRNA Stability and Gene Expression
5.6K
The structure and stability of mRNA molecules regulates gene expression, as mRNAs are a key step in the pathway from gene to protein. In eukaryotes, the half-life of mRNA varies from a few minutes up to several days. mRNA stability is essential in growth and development. The absence of the proteins regulating its stability, such as tristetraprolin in mice, can cause systemic issues, including bone marrow overgrowth, inflammation, and autoimmunity.
Cis-acting Elements involved in mRNA stability
Cis-acting Elements involved in mRNA stability
5.6K
01:53RNA Stability
33.6K
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
33.6K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:22MicroRNAs
21.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.4K